(2R)-2-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethanal | 171560-20-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethanal
• 英文别名: (R)-tert-butyl (1-cyclohexyl-2-oxoethyl)carbamate；((R)-1-cyclohexyl-2-oxo-ethyl)-carbamic acid tert-butyl ester；tert-butyl N-[(1R)-1-cyclohexyl-2-oxoethyl]carbamate
• CAS: 171560-20-6
• 化学式: C₁₃H₂₃NO₃
• 分子量: 241.331
• InChiKey: BDSGOSWEKUGHOV-NSHDSACASA-N

物化性质

• 沸点：
  347.8±25.0 °C(Predicted)
• 密度：
  1.030±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R)-2-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethanal 在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑 、 sodium hydrogensulfite 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 反应 18.0h， 生成 (S)-2-((R)-3-Amino-3-cyclohexyl-2-hydroxy-propionylamino)-propionic acid ethyl ester
  参考文献：
  名称：

  3-氨基-2-羟酰胺和相关化合物作为蛋氨酸氨基肽酶-2的抑制剂。

  摘要：

  取代的3-氨基-2-羟基酰胺和相关的羟基酰胺和酰基肼被鉴定为人甲硫氨酸氨基肽酶2（MetAP2）的抑制剂。通过平行合成和基于迭代结构的设计检查取代基，可以鉴定出对MetAP1具有良好选择性的强效抑制剂。二酰基肼3t（A-357300）被鉴定为对人微血管内皮细胞（HMVEC）的蛋氨酸加工和细胞增殖具有抑制作用的类似物。

  DOI：

  10.1016/j.bmcl.2003.12.031
• 作为产物：
  描述：

  ((S)-2-cyclohexyl-2-hydroxyethyl)carbamic acid tert-butyl ester 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以100%的产率得到(2R)-2-(1,1-dimethylethoxycarbonylamino)-2-cyclohexylethanal
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE
  [FR] AMINO-BENZIMIDAZOLES SUBSTITUÉS, MÉDICAMENTS COMPRENANT LEDIT COMPOSÉ, LEUR UTILISATION ET LEUR PROCÉDÉ DE FABRICATION

  摘要：

  本发明涉及一般式（1）中的取代氨基苯并咪唑，其中基团R1至R14和A如规范和索赔中定义，并其用于治疗阿尔茨海默病（AD）和类似疾病。

  公开号：

  WO2009092566A1

文献信息

• MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)
  申请人：Baxter W. Ellen

  公开号：US20070232630A1

  公开（公告）日：2007-10-04

  The present invention is directed to macrocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.

  本发明涉及大环衍生物，含有它们的药物组合物以及它们在治疗阿尔茨海默病（AD）及相关疾病中的应用。本发明的化合物是β-分泌酶的抑制剂，也被称为β-位点裂解酶和BACE、BACE1、Asp2和memapsin2。
• Chiral Aminal Templates: Diastereoselective Addition to Hydrazones; An Asymmetric Synthesis of α-Amino Aldehydes
  作者：Alex Alexakis、Nathalie Lensen、Jean-Philippe Tranchier、Pierre Mangeney、J. Feneau-Dupont、J. P. Declercq

  DOI：10.1055/s-1995-4042

  日期：1995.8

  The monohydrazone of glyoxal may be derivatized into a chiral aminal with diamine 7. The resulting chiral reagent 13 reacts with complete diastereocontrol with organolithium reagents in THF. This sterically controlled reaction may be altered to chelation control by using Grignard reagents in toluene, affording the opposite diastereomer in excellent de. The N-N bond of the hydrazine functionality is then cleaved with Raney nickel, assisted by ultrasound. After protection of the resulting primary amino functionality, the aminal is hydrolyzed to afford the desired α-amino aldehydes without epimerization. The same reaction sequence, without cleavage of the N-N bond, affords an α-hydrazino aldehyde.

  乙二醛的单氢肼可与二胺7衍生化为一个手性氨胺。所得的手性试剂13在四氢呋喃中与有机锂试剂反应，具有完全的非对映体选择性。通过在甲苯中使用格氏试剂，这一立体控制反应可被改变为螯合控制，从而生成相反的非对映体，并获得优异的对映选择性。接着，利用超声波的辅助下，水合肼的N-N键被拉尼镍裂解。在保护产物中的初级氨基功能基后，氨胺被水解，生成所需的α-氨基醛而不发生表异构化。相同的反应序列，如果不裂解N-N键，则会生成α-肼醛。
• Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potent β-secretase inhibitors
  作者：Arun K. Ghosh、Satyendra Pandey、Sudhakar Gangarajula、Sarang Kulkarni、Xiaoming Xu、Kalapala Venkateswara Rao、Xiangping Huang、Jordan Tang

  DOI：10.1016/j.bmcl.2012.07.043

  日期：2012.9

  Structure-based design, synthesis, and biological evaluation of a series of dihydroquinazoline-derived β-secretase inhibitors incorporating thiazole and pyrazole-derived P2-ligands are described. We have identified inhibitor 4f which has shown potent enzyme inhibitory (Ki = 13 nM) and cellular (IC50 = 21 nM in neuroblastoma cells) assays. A model of 4f was created based upon the X-ray structure of

  描述了一系列包含噻唑和吡唑衍生 P2-配体的二氢喹唑啉衍生 β-分泌酶抑制剂的基于结构的设计、合成和生物学评价。我们已鉴定出抑制剂4f，其在酶抑制 (K i  = 13 nM) 和细胞 (IC 50  = 21 nM 在神经母细胞瘤细胞中) 测定中表现出强效。基于3a结合 β-分泌酶的 X 射线结构创建了4f模型。该模型建议了活性位点中可能的相互作用。
• Binding cooperativity between a ligand carbonyl group and a hydrophobic side chain can be enhanced by additional H-bonds in a distance dependent manner: A case study with thrombin inhibitors
  作者：Ahmed M. Said、David G. Hangauer

  DOI：10.1016/j.ejmech.2015.03.059

  日期：2015.5

  One of the underappreciated non-covalent binding factors, which can significantly affect ligand-protein binding affinity, is the cooperativity between ligand functional groups. Using four different series of thrombin inhibitors, we reveal a strong positive cooperativity between an H-bond accepting carbonyl functionality and the adjacent P3 hydrophobic side chain. Adding an H-bond donating amine adjacent to the P3 hydrophobic side chain further increases this positive cooperativity thereby improving the Ki by as much as 546-fold. In contrast, adding an amidine multiple H-bond/salt bridge group in the distal S1 pocket does not affect this cooperativity. An analysis of the crystallographic B-factors of the ligand groups inside the binding site indicates that the strong cooperativity is mainly due to a significant mutual reduction in the residual mobility of the hydrophobic side chain and the H-bonding functionalities that is absent when the separation distance is large. This type of cooperativity is important to encode in binding affinity prediction software, and to consider in SAR studies. (C) 2015 Elsevier Masson SAS. All rights reserved.
• WO2007/50612
  申请人：——

  公开号：——

  公开（公告）日：——